TUBULOINTERSTITIAL NEPHRITIS WITH IGM-POSITIVE PLASMA CELLS SUCCESSFULLY TREATED WITH CYCLOSPORINE MONOTHERAPY: A CASE REPORT

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
 
TUBULOINTERSTITIAL NEPHRITIS WITH IGM-POSITIVE PLASMA CELLS SUCCESSFULLY TREATED WITH CYCLOSPORINE MONOTHERAPY: A CASE REPORT

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Shuntaro
Kita
Shuntaro Kita kyokui150031@gmail.com Asahikawa Medical University Division of Cardiology and Nephrology, Department of Internal Medicine Asahikawa Japan *
Momoko Nambu moco@asahikawa-med.ac.jp Asahikawa Medical University Division of Cardiology and Nephrology, Department of Internal Medicine Asahikawa Japan -
Saeko Uchida-Miura saekou@asahikawa-med.ac.jp Kitasaito Hospital Department of Internal Medicine Asahikawa Japan -
Reina Suetsugu-Ishizawa kyokui120084@gmail.com Asahikawa Medical University Division of Cardiology and Nephrology, Department of Internal Medicine Asahikawa Japan -
Megumi Matsumoto kyokui110100@gmail.com Asahikawa Medical University Division of Cardiology and Nephrology, Department of Internal Medicine Asahikawa Japan -
Hirofumi Sakuma hsakuma210@asahikawa-med.ac.jp Asahikawa Medical University Division of Cardiology and Nephrology, Department of Internal Medicine Asahikawa Japan -
Motoki Matsuki motoki@asahikawa-med.ac.jp Asahikawa Medical University Division of Cardiology and Nephrology, Department of Internal Medicine Asahikawa Japan -
Naoki Takahashi ntakahas@u-fukui.ac.jp University of Fukui Hospital Department of Clinical Laboratory Fukui Japan - University of Fukui Department of Nephrology, Faculty of Medical Sciences Fukui Japan
Tadashi Toyama ttoyama@u-fukui.ac.jp University of Fukui Hospital Department of Clinical Laboratory Fukui Japan - University of Fukui Department of Nephrology, Faculty of Medical Sciences Fukui Japan
Naoki Nakagawa naka-nao@asahikawa-med.ac.jp Asahikawa Medical University Division of Cardiology and Nephrology, Department of Internal Medicine Asahikawa Japan -